308 results
8-K
EX-99.1
LLY
Lilly(Eli) & Co
30 Apr 24
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
7:04am
increase was primarily driven by growth from Mounjaro, Zepbound®, Verzenio and Jardiance, partially offset by declines in Trulicity®. Strong demand … and Verzenio
Q1 2024 as growth led by Verzenio, Jardiance, Taltz® and Emgality® was largely offset by lower Trulicity sales.
Revenue in the U.S
8-K
EX-99.1
5sd3ho2
6 Feb 24
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
7:04am
8-K
EX-99.1
80vrnk s6df6
2 Nov 23
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
7:02am
CORRESP
tynbenh6f4 04
26 Oct 23
Correspondence with SEC
12:00am
UPLOAD
9wvfg8z5c b4jzt7
29 Sep 23
Letter from SEC
12:00am
CORRESP
zegfvwoh8he3 usgxs
20 Sep 23
Correspondence with SEC
12:00am
8-K
EX-99.1
0wgtr 1s3th6bm
8 Aug 23
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
7:01am
8-K
EX-99.01
rgua8y12
27 Apr 23
Results of Operations and Financial Condition
7:02am
8-K
EX-99
q334n0e0xbdr3dn
13 Dec 22
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
7:03am
8-K
EX-99.1
u2qbiuqo3uloqemgd
1 Nov 22
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
7:03am